Send me real-time posts from this site at my email

Watchlist Update: 1-17-2019 - Amarin - AMRN - Analyst comments

H.C. Wainwright reiterates $51 price target on Amarin shares - $AMRN

H.C. Wainwright analyst Andrew Fein reiterates an Buy rating on Amarin with a $51 price target after hosting a meeting with management during the JPMorgan Healthcare conference. Management noted that the majority of physician feedback post American Heart Association was positive towards Vascepa, Fein tells investors in a research note.

Read more at: (source)

* This stock has been on our trading list for a while now. Will continue to look for trades in this name. *

Tiger's Take: "Good longer term medical holding with some short term trading opps."

$AMRN, Amarin Corporation plc / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions.

Follow us and check back occasionally for additional articles or posts.

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue